Acrotech Biopha

MARQIBO

Manufacturer:

Acrotech Biopha

Marqibo HCPCS:

J9371

HCPCS Code Descriptor:

Injection, vincristine sulfate liposome, 1 mg

Category:

J Code

Marqibo NDCs:

72893-0008-03

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Multiple

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

72893-0008-03

About Marqibo:

MARQIBO is an Oncology drug manufactured by Acrotech Biopha and administered via the Intravenous route of administration. The J Code: J9371 is aligned to the drug MARQIBO.

ACCESS PRICING AND MORE BY REGISTERING

J9371 Added Date:

January 1, 2014

J9371 Effective Date:

January 1, 2014

J9371 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Marqibo billing and coding information.
Marqibo patient assistance information can be found through Acrotech Patient Access at the URL: https://acrotechpatientaccess.com/patient-assistance-program/
MARQIBO prescribing information can be found at the link below:
Information regarding MARQIBO’s side effects can be found at MedlinePlus